Form 4: Capricor Therapeutics Director Collier Jr. Awarded Stock Options

Director Earl M. Collier Jr. of Capricor Therapeutics was granted multiple stock options on January 2, 2025, as part of his annual board service and committee service.

Summary

• Earl M. Collier Jr., a director at Capricor Therapeutics, received stock options on January 2, 2025.
• These options are divided into three grants: 11,940 shares vesting monthly starting February 1, 2025, 3,240 shares fully vested immediately, and 5,750 shares fully vested immediately.
• The exercise price for all options is $14.96 per share, and they expire on January 2, 2035.
• The first grant of 11,940 shares vests over 12 months, with the option to early exercise, which would result in restricted stock subject to repurchase if service terminates before vesting.
• The other two grants of 3,240 and 5,750 shares are fully vested and exercisable immediately as of the grant date.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, which is generally positive for aligning director interests with company performance. There are no negative implications.

Positives

• The stock options serve as an incentive for director Earl M. Collier Jr.
• The vesting schedule of the 11,940 options encourages continued service to the company.
• The immediate vesting of 8,990 options provides immediate value to the director.

Risks

• The early exercise feature of the vesting options introduces a risk of share repurchase if the director's service terminates before full vesting.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for board members across the biotechnology industry.
• The vesting schedule of 1/12th per month is a common vesting structure.
• The 10-year expiration period is also typical for stock options.

Stakeholder Impact

• The stock options align the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, director compensation, equity awards, insider trading, Capricor Therapeutics, CAPR, vesting, Form 4